Ipamorelin, CJC-1295 and Cancer: Is There Any Evidence?

In this article, we will take a close look at Ipamorelin and CJC-1295, two types of peptides often used in combination due to their synergistic effects. We will delve into their functions, their use in the fitness and anti-aging communities, and discuss the complex relationship between these peptides and cancer risk.
Natasha Puttick

Natasha Puttick

Graduate medical student at Barts and London.

A blue image with text saying "Understanding the Effects of Ipamorelin and CJC-1295"

What are Ipamorelin and CJC-1295?

Ipamorelin and CJC-1295 are two types of peptides that are often used in combination due to their synergistic effects.

Ipamorelin is a pentapeptide, which means it consists of five amino acids, that signals the pituitary gland to produce growth hormone. This peptide is considered one of the safest growth hormone-releasing peptides and does not affect cortisol or prolactin levels in the body. It has a strong growth hormone releasing potency and efficacy, both in vitro and in vivo [1].

CJC-1295, on the other hand, is a synthetic peptide that also stimulates growth hormone release. It functions by mimicking the natural growth hormone releasing hormone (GHRH), which is responsible for growth hormone production in the body.

When used together, these two peptides can effectively increase the body's natural production of growth hormone, leading to improved muscle growth and fat loss. However, it's important to note that while these peptides are often used in the fitness and anti-aging communities, their use should be supervised by a healthcare professional due to potential side effects and interactions. You can also see our blog comaring ipamorelin and hexarelin.

Can Ipamorelin cause cancer?

There may not be sufficient evidence to answer exactly whether ipamorelin can cause cancer. However, it's important to note that ipamorelin, like other growth hormone-releasing peptides, can stimulate the release of growth hormone (GH) and insulin-like growth factor-1 (IGF-1) [2].

In some studies, it has been suggested that overexpression of IGF-1 and its receptor could potentially stimulate tumor growth. However, this does not directly imply that ipamorelin can cause cancer, as the relationship between GH, IGF-1, and cancer is complex and not fully understood.

In a study investigating the effects of anamorelin, a similar GH-releasing peptide, on cancer patients with cachexia, it was found that anamorelin did not promote tumor growth in a murine non-small cell lung cancer model, despite increased levels of GH and a trend of increased IGF-1 [3].

It's important to note that these findings may not directly apply to ipamorelin, as the two peptides, while similar, are not identical. More research is needed to fully understand the potential effects of ipamorelin on cancer risk.

The link between peptides and cancer is unclear. For example, in our previous blogs, we found that cancer can be a side effect of MK-677 and thymosin beta 4 impacts tumor growth, but there is limited evidence for the link between BPC-157 and cancer.

In the case of sermorelin, some studies suggest that Sermorelin can stimulate the proliferation of certain types of cancers, while others suggest it could be used as a potential cancer treatmet.

Searching for the answer?

Let's be honest, you just wanted a quick, direct answer to your question. That's why we createdMediSearch- a free, science-based search for medical information.

Can CJC 1295 cause cancer?

Similarly to Ipamorelin there may not be sufficient evidence to answer exactly whether CJC 1295 can cause cancer. The current body of research does not contain specific information about the peptide CJC 1295 and its potential to cause cancer. As the relationship between CJC 1295 and cancer has not been clearly established in the provided studies, if you have any concerns, always consult with a healthcare provider when considering the use of substances like CJC 1295.

If you are interested in CJC 1295, consider reading our blog about the impact of CJC 1295 on the heart.

Related Posts

Natasha Puttick

Natasha Puttick

Natasha is a medical student at Barts and the London school of Medicine and Dentistry, with an interest in the social determinants of health. She graduated from the University of Oxford with a BA in Human Sciences and has obtained two publications. Her most recent work investigating clinical vaccine trials has been published in BMJ Public Health.